Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Megestrol acetate + Premarin is a combination therapy consisting of megestrol acetate (a synthetic progestin) and conjugated estrogens (marketed as Premarin). Megestrol acetate acts primarily as an agonist of the progesterone receptor, exerting antigonadotropic effects and weak glucocorticoid activity. Conjugated estrogens are a mixture of estrogenic compounds that act as agonists at the estrogen receptor. This combination has been studied in hormone-responsive advanced breast cancer to assess whether sequential administration improves outcomes compared to progestin alone. The mechanism involves modulation of hormone receptors in target tissues; however, clinical trials have not shown superiority over single-agent progestin therapy for this indication[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on megestrol acetate + conjugated estrogens.